Hospital Universitari Germans Trias i Pujol -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

2017

  1. Predictive and prognostic brain metastases assessment in luminal breast cancer patients: FN14 and GRP94 from diagnosis to prophylaxis

    Frontiers in Oncology, Vol. 7, Núm. DEC

2015

  1. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

    Oncotarget, Vol. 6, Núm. 42, pp. 44254-44273

2014

  1. Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors

    Medical Oncology, Vol. 31, Núm. 1

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

2008

  1. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer

    Cancer Treatment Reviews, Vol. 34, Núm. 8, pp. 701-709

2004

  1. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase II trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

    Annals of Oncology, Vol. 15, Núm. 1, pp. 79-87